Aligos Therapeutics, Inc. (ALGS)
NASDAQ: ALGS · Real-Time Price · USD
4.250
+0.170 (4.17%)
Jul 28, 2026, 11:59 AM EDT - Market open
Aligos Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 29.98 | 18.3 | 37 | 135.7 | 81.35 | 186.82 |
Short-Term Investments | 24.93 | 59.54 | 19.94 | - | 44.48 | 3.92 |
Cash & Short-Term Investments | 54.91 | 77.84 | 56.94 | 135.7 | 125.83 | 190.73 |
Cash Growth | -60.17% | 36.71% | -58.04% | 7.85% | -34.03% | -21.67% |
Other Current Assets | 4.72 | 5.02 | 5.2 | 5.38 | 7.72 | 13.69 |
Total Current Assets | 59.63 | 82.86 | 62.14 | 141.08 | 133.55 | 204.42 |
Net Property, Plant & Equipment | 4.17 | 4.96 | 7.33 | 9.82 | 12.51 | 14.97 |
Long-Term Investments | - | - | - | - | - | 15.11 |
Other Long-Term Assets | 0.76 | 0.72 | 0.63 | 0.63 | 0.63 | 0.87 |
Total Assets | 64.56 | 88.53 | 70.09 | 151.53 | 146.69 | 235.37 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 7.64 | 3.98 | 2.57 | 2.52 | 4.74 | 3.02 |
Accrued Expenses | 11.99 | 13.53 | 15.56 | 16.84 | 16.04 | 25.39 |
Current Portion of Leases | 3.69 | 3.73 | 3.46 | 3.24 | 3.14 | 2.91 |
Unearned Revenue | - | - | 0.15 | 1.31 | 9.21 | 7.64 |
Total Current Liabilities | 23.32 | 21.23 | 21.74 | 23.91 | 33.13 | 38.96 |
Long-Term Leases | 0.66 | 1.53 | 4.92 | 7.9 | 9.43 | 11.55 |
Other Long-Term Liabilities | 8.79 | 12.23 | 72.41 | 27.64 | 0.23 | 0.13 |
Total Long-Term Liabilities | 9.45 | 13.76 | 77.33 | 35.54 | 9.66 | 11.68 |
Total Liabilities | 32.77 | 34.99 | 99.07 | 59.45 | 42.79 | 50.64 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0 | 0 |
Additional Paid-in Capital | 696.58 | 695.27 | 588.58 | 578.33 | 502.61 | 487.35 |
Accumulated Other Comprehensive Income | 0.44 | 0.47 | 0.45 | 0.55 | 0.4 | 0.45 |
Retained Earnings | -665.24 | -642.2 | -618.01 | -486.8 | -399.12 | -303.07 |
Shareholders' Equity | 31.79 | 53.55 | -28.97 | 92.08 | 103.9 | 184.73 |
Total Liabilities & Equity | 64.56 | 88.53 | 70.09 | 151.53 | 146.69 | 235.37 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 4.35 | 5.25 | 8.38 | 11.14 | 12.57 | 14.46 |
Net Cash (Debt) | 50.56 | 72.59 | 48.56 | 124.57 | 113.25 | 176.28 |
Net Cash Growth | -61.11% | 49.48% | -61.01% | 9.99% | -35.75% | -23.52% |
Net Cash Per Share | 4.87 | 7.34 | 7.75 | 48.59 | 66.31 | 110.57 |
Book Value | 31.79 | 53.55 | -28.97 | 92.08 | 103.9 | 184.73 |
Book Value Per Share | 3.06 | 5.42 | -4.62 | 35.92 | 60.84 | 115.87 |
Tangible Book Value | 31.79 | 53.55 | -28.97 | 92.08 | 103.9 | 184.73 |
Tangible Book Value Per Share | 3.06 | 5.42 | -4.62 | 35.92 | 60.84 | 115.87 |